The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 37,032 |
| Depreciation and amortization | 15,273 |
| Amortization of intangible assets | 3,323 |
| Reduction in the carrying value of right-of-use assets | 8,342 |
| Non-cash interest expense | 375 |
| Deferred tax expense (benefit) | 9,500 |
| Loss on disposal of property and equipment | -188 |
| Provision recorded for credit losses | 8,213 |
| Adjustment for excess and obsolete inventories | -15,353 |
| Stock-based compensation | 13,298 |
| Write-down to fair value for asset held for sale (note 8) | 11,175 |
| Accounts receivable | 115,803 |
| Inventories | 17,915 |
| Prepaid expenses and other current and other assets | 183 |
| Operating leases | 8,491 |
| Accounts payable | -528 |
| Accrued expenses and other current liabilities | 10,381 |
| Other liabilities | 158 |
| Net cash provided by (used in) operating activities | -10,309 |
| Purchases of property and equipment | 14,151 |
| Net cash used in investing activities | -14,151 |
| Construction of landlord assets, net of tenant allowance | 14,461 |
| Principal repayments of finance lease obligations | 1,171 |
| Proceeds from the exercise of stock options | 157 |
| Payments of withholding taxes in connection with rsus vesting | 1,885 |
| Net cash provided by (used in) financing activities | -17,360 |
| Change in cash, cash equivalents and restricted cash | -41,820 |
| Cash, cash equivalents and restricted cash, beginning of year | 136,151 |
| Cash, cash equivalents and restricted cash, end of year | 94,331 |
Organogenesis Holdings Inc. (ORGO)
Organogenesis Holdings Inc. (ORGO)